Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic dermatitis. EVO301's multi-pathway IL-18 inhibition offers broad potential, but ...
Montreal, Quebec--(Newsfile Corp. - September 9, 2025) - Manganese X Energy Corp. (MN:CA) (FSE: 9SC) (TRADEGATE: 9SC) (OTCQB: MNXXF) ("Manganese X" or the "Company") is pleased to announce it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results